The latest price target for Silence Therapeutics (NASDAQ:SLN) was reported by Goldman Sachs on February 11, 2025. The analyst firm set a price target for $6.00 expecting SLN to rise to within 12 months (a possible 25.26% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Silence Therapeutics (NASDAQ:SLN) was provided by Goldman Sachs, and Silence Therapeutics initiated their sell rating.

There is no last upgrade for Silence Therapeutics

There is no last downgrade for Silence Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Silence Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Silence Therapeutics was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.

While ratings are subjective and will change, the latest Silence Therapeutics (SLN) rating was a initiated with a price target of $0.00 to $6.00. The current price Silence Therapeutics (SLN) is trading at is $4.79, which is within the analyst’s predicted range.